PubRank

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk (REDUCE)

Clinical Trial ID NCT00056407

PubWeight™ 47.27‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00056407

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010 12.78
2 Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol 2012 2.34
3 PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol 2010 2.33
4 Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Urology 2011 2.28
5 Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. BMJ 2013 2.21
6 Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol 2012 1.81
7 The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2010 1.73
8 Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev 2012 1.63
9 Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int 2011 1.54
10 Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. Urology 2009 1.45
11 Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. J Urol 2011 1.44
12 Biopsy misidentification identified by DNA profiling in a large multicenter trial. J Clin Oncol 2011 1.44
13 Prostate needle biopsy quality in reduction by dutasteride of prostate cancer events study: worldwide comparison of improvement with investigator training and centralized laboratory processing. Urology 2009 1.44
14 Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. Eur Urol 2013 1.02
15 Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. Cancer Epidemiol Biomarkers Prev 2014 0.98
16 Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis 2011 0.97
17 Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res 2014 0.96
18 Low serum testosterone levels are poor predictors of sexual dysfunction. BJU Int 2010 0.90
19 Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). J Intern Med 2012 0.87
20 Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial. Urology 2011 0.86
21 A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk. Genet Epidemiol 2012 0.84
22 Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. Int J Biol Sci 2016 0.81
23 Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study. Prostate 2015 0.81
24 Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial. Appl Health Econ Health Policy 2011 0.79
25 Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE. Prostate Cancer Prostatic Dis 2016 0.78
26 Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study. Cancer Prev Res (Phila) 2015 0.77
27 Do omega-3 polyunsaturated Fatty acids prevent cardiovascular disease? A review of the randomized clinical trials. Lipid Insights 2013 0.76
28 Results from the reduce trial on the effect of prostate size on incident lower urinary tract symptoms in men with mild to no current symptoms: do they justify prophylactic intervention? Transl Androl Urol 2016 0.75
29 Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy. J Urol 2015 0.75
Next 100